GlassScriptPhysician profile
Mohammadreza Tabesh
NPI 1528131562
$4,327.83
in general payments reported to CMS, 2019-2025
30 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $91.84 · 2021: $271 · 2022: $364 · 2023: $350 · 2024: $926 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540 · Travel and Lodging: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.11 |
| Travel and Lodging | $1,172.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,496.34 | 2019-2025 | Triclip, Navitor, Cardiomems |
| Edwards Lifesciences Corporation | $880.42 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abiomed | $269.95 | 2023-2025 | Impella |
| Inari Medical, INC. | $222.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $214.60 | 2019-2021 | |
| Boston Scientific Corporation | $206.33 | 2019-2023 | |
| Pfizer INC. | $142.89 | 2019-2023 | |
| Medtronic, INC. | $139.75 | 2021-2025 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $123.07 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $68.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.81 | 2022-2024 | Jardiance |
| Chiesi USA, INC. | $42.77 | 2019 | |
| Penumbra, INC. | $37.97 | 2022-2023 | Indigo System |
| Alnylam Pharmaceuticals INC. | $37.17 | 2024-2025 | Onpattro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.79 | 2021-2022 | |
| Cvrx, INC. | $33.17 | 2022 | |
| Cook Medical LLC | $33.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.66 | 2019-2023 | |
| Novo Nordisk INC | $25.55 | 2025 | Wegovy |
| Heartflow, INC. | $24.84 | 2025 | |
| Atricure, INC. | $24.78 | 2023 | |
| Medtronic Vascular, INC. | $24.76 | 2019 | |
| Csl Behring | $20.40 | 2019 | |
| Portola Pharmaceuticals, LLC | $19.36 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.81 | 2019 | |
| Amarin Pharma, INC. | $17.82 | 2019 | |
| Elutia, INC. | $15.87 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.27 | 2019 | |
| Cardiovascular Systems INC. | $3.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammadreza Tabesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.